Mariner
RNAM

Mariner’s Avidity Biosciences RNAM Stock Holding History

Mariner’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-9,728
Closed -$287K – 3647
2025
Q1 		$287K Buy
9,728
+2,240
+30% +$69.8K ﹤0.01% 2667
2024
Q4 		$218K Sell
7,488
-1,836
-20% -$76.7K ﹤0.01% 2932
2024
Q3 		$427K Buy
9,324
+2,082
+29% +$90.3K ﹤0.01% 2269
2024
Q2 		$296K Buy
+7,242
New +$208K ﹤0.01% 2460

Other funds holding RNAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Mariner's RNAM Position: Q2 2025 in Review

Mariner sold out of Avidity Biosciences (RNAM) in Q2 2025, closing a stake of 9,728 shares — an estimated $287K sold.

Mariner first reported a position in RNAM in Q2 2024 and held it in 4 quarters. The position peaked at $427K in Q3 2024. 206 funds tracked by Wall St. Rank hold RNAM as of Q2 2025.

  • Mariner reported no remaining Avidity Biosciences position as of Q2 2025 after selling out during the quarter.
  • Mariner sold 9,728 Avidity Biosciences shares in Q2 2025, an estimated $287K.
  • Mariner first reported a position in Avidity Biosciences in Q2 2024 and held it in 4 quarters.
  • Mariner's Avidity Biosciences position peaked at $427K in Q3 2024.
  • 206 funds tracked by Wall St. Rank held Avidity Biosciences as of Q2 2025.

Based on Mariner's 13F filing for Q2 2025, filed 14 Aug 2025.